SDN Members don't see this ad. (About Ads) The research pipeline is full of junk. More monoclonal antibodies with limited efficacy....specialized chemotherapy on the newest receptor pathway (JAK)...and more rehashes and drug combos. We're only getting 1 new abx a year....pitiful. Oh look, another insulin analog. Great stuff! And then we have this Alzheimer's marker that doesn't haven great diagnostic accuracy. Such a shame.